Adoptive immunotherapy agent CTL019
Acute lymphoblastic leukemia and Diffuse large B cell lymphoma
Patent oppositions filed in
Europe (EPO)

Tisagenlecleucel is a CD-19 directed genetically modified autologous T-cell immunotherapy. It is approved for the treatment of Acute lymphoblastic leukemia (ALL).

This drug is missing the following documents, can you help us by contributing something?


Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
Europe (EPO)02-07-2019Médecins du MondePost-GrantPatent revoked OtherEP3214091 View/Comment
Europe (EPO)02-07-2019Miltenyi Biotec GmbHPost-GrantPatent RevokedOtherEP3214091View/Comment
Europe (EPO)03-07-2019Cabinet PLASSERAUDPost-GrantPatent RevokedOtherEP3214091View/Comment
Europe (EPO)02-07-2019Public EyePost-GrantPatent RevokedOtherEP3214091View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top

Patent Office Decisions

This table showcases the final ruling of patent offices over cases where patents have been opposed.

To better identify the case, the number of the patent application is provided in the table below.

Decision typeCountryDatePatent officeRelated patent applicationMore info
RejectionEurope (EPO)09-12-2019EPOEP3214091 View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top